SLAMF6 as a drug

Nature ( 2026 ) Cite this article
The Original Article was published on 11 February 2026
Correction to: Nature https://doi.org/10.1038/s41586-026-10106-5 Published online 11 February 2026
In the version of this article initially published, in the first paragraph of the Discussion, citation of a recent report showing that aberrant expression of SLAMF6 on human acute myelogenous leukemia cells suppressed T cell activation, an effect that was prevented by a blocking SLAMF6 mAb (Sandén, C.

et al.

Nat.

Cancer https://doi.org/10.1038/s43018-025-01054-6 (2026)), was missing and is now included in the HTML and PDF versions of the article.

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montreal, Quebec, Canada
Bin Li, Ming-Chao Zhong, Cristian Camilo Galindo, Jiayu Dou, Jin Qian, Zhenghai Tang, Dominique Davidson & André Veillette
Department of Medicine, University of Montréal, Montreal, Quebec, Canada
Department of Medicine, McGill University, Montreal, Quebec, Canada
Bin Li, Cristian Camilo Galindo, Jiayu Dou & André Veillette
Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China
MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China
Search author on: PubMed Google Scholar
Correspondence to André Veillette .

Version of record : 13 March 2026
DOI : https://doi.org/10.1038/s41586-026-10376-z